RSS   Newsletter   Contact   Advertise with us

Venkatadri Bobba joins Cancer Genetics India's board

Share on Twitter Share on LinkedIn
Staff writer | Hyderabad, India | December 17, 2014
Cancer GeneticsDecember 17, 2014, Hyderabad, India - Cancer Genetics, Inc., a DNA-based cancer diagnostics commpany, announced the addition of Venkatadri Bobba to Cancer Genetics India's board of directors.
Mr. Bobba brings with him more than 36 years of corporate leadership experience in the pharmaceutical and life sciences industries. Mr. Bobba, who is currently a General Partner with Ventureast, has held executive leadership positions at a number of life sciences companies in the US, EU, and Asia.

Prior to joining Ventureast, he served as Senior Vice President of Operations at Aradigm Corporation and from 2001-2003 was Executive Vice President at Diosynth, a division of Akzo Nobel. From 1995 to 2000, he served as President and CEO at Molecular Biosystems, an NYSE listed company.

Previous to that, Mr. Bobba was Executive Vice President of Centocor Inc (now Jansen Biotech, a division of Johnson & Johnson) and held several executive positions, including President, at Warner-Lambert, Indonesia. He also previously served as V.P. of Manufacturing at Parke-Davis, USA (now part of Pfizer).

Mr. Bobba is an active board member of three US-based companies, including Diabetomics Inc., Melior Pharma, and Sparsha Inc. He also sits on the board of several Indian-based companies, including Portea, Richcore, and Sparsha Pharma, an Indian subsidiary of Napo Pharmaceuticals. Additionally, he serves on the advisory board for the SOHO Group, the largest pharmaceutical company in Indonesia, and for Cumberland Pharmaceuticals, Inc., USA, a Nasdaq listed company.

A pharmacist by training, Mr. Bobba graduated with gold medal honors from Andhra University and holds an MBA from Farleigh Dickinson University, New Jersey.